Company research
Quantum Biopharma Ltd.
CIK 1771885Updated Sep 24, 2026
SecuritiesQNTM · CSE · equityQNTM · NASDAQ · equity
Historical securities (1)
QNTM · NEO · equity · closed Oct 1, 2024Name history
FSD Pharma Inc. · through Aug 15, 2024
QNTM price & chart
Loading TradingView…
CSE:QNTM on TradingView ↗In the news
Quantum BioPharma Ltd. NASDAQ: QNTM) Receives FDA Clearance to Begin Trials for Historic MS Treatment ↗
Quantum BioPharma Strengthens Equity and Liquidity in Q2 2026 as FDA Approves Lucid-MS for Pivotal Phase 2 Clinical Trial ↗
Quantum BioPharma Announces Closing of Debt Settlement ↗
Recent filings
Show 5 more recent filings
Financials
FY 2025 · USDSource
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Profit or LossUSD | — | — | — | -23,606,828Source |
| Additional Financial Items | ||||
| AdjustmentsForFinanceIncomeUSD | -1,491,001Source | -4,663,014Source | 663,698Source | 7,431,656Source |
| AdjustmentsForIncreaseDecreaseInTradeAccountPayableUSD | 1,178,497Source | — | — | — |
| AdjustmentsForSharebasedPaymentsUSD | 2,945,502Source | — | 16,702Source | 1,531,258Source |
| AdjustmentsForUnrealisedForeignExchangeLossesGainsUSD | — | — | — | 934,100Source |
| GeneralAndAdministrativeExpenseUSD | — | 9,410,097Source | 9,032,724Source | 14,450,094Source |
| PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivitiesUSD | 113,862Source | 63,586Source | 189,054Source | 143,071Source |
| ProceedsFromBorrowingsClassifiedAsFinancingActivitiesUSD | 2,113,386Source | — | — | — |
| ProceedsFromIssuingSharesUSD | 338,331Source | 10,670,618Source | 34Source | 0Source |
| ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodUSD | 1,181,499Source | -6,189,077Source | 443,138Source | 158,036Source |
| PurchaseOfIntangibleAssetsClassifiedAsInvestingActivitiesUSD | — | 0Source | 0Source | 250,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Selling, General and Administrative ExpenseUSD | 9,047,918Source | — | — | — |
| Additional Financial Items | ||||
| ApplicableTaxRatenumber | 0.27Source | 0.27Source | 0.27Source | 0.27Source |
| DeferredTaxExpenseIncomeUSD | — | — | 0Source | 0Source |
| DepreciationAndAmortisationExpenseUSD | 545,780Source | 490,571Source | 2,506,316Source | 4,537,415Source |
| DepreciationRightofuseAssetsUSD | — | — | — | 114,907Source |
| ExpenseFromSharebasedPaymentTransactionsWithEmployeesUSD | 2,945,502Source | 152,214Source | 3,835,475Source | 1,531,258Source |
| FinanceCostsUSD | 158,063Source | 33,017Source | 299Source | 48,822Source |
| GeneralAndAdministrativeExpenseUSD | — | 9,410,097Source | 9,032,724Source | 14,450,094Source |
| InterestExpenseUSD | — | 9,343Source | 24,288Source | 149,906Source |
| InterestExpenseOnLeaseLiabilitiesUSD | — | — | — | 19,062Source |
| OtherIncomeUSD | 1,946,491Source | 3,989Source | — | — |
| ProfessionalFeesExpenseUSD | 3,278,735Source | 3,074,130Source | 3,248,233Source | 5,208,356Source |
| ProfitLossAttributableToNoncontrollingInterestsUSD | -26,956,840Source | -14,915,529Source | -18,230,588Source | — |
| ProfitLossFromOperatingActivitiesUSD | -15,302,374Source | — | — | -27,429,611Source |
| ResearchAndDevelopmentExpenseUSD | 2,763,174Source | 6,083,378Source | 3,859,178Source | 6,910,844Source |
| RevenueFromInterestUSD | — | — | 568,919Source | 183,037Source |
| SellingExpenseUSD | — | — | — | 616,002Source |